The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Epithelial-mesenchymal transition and inflammation at the site of the primary tumor
Open accessAbstract
Tumor growth and progression are the products of complex signaling networks between different cell types within the tumor and its surrounding stroma. In particular, established tumors are known to stimulate an inflammatory reaction via the secretion of cytokines, chemokines, and growth factors that favor the recruitment of a range of infiltrating immune cell populations into the tumor microenvironment. While potentially able to exert tumor control, this inflammatory reaction is typically seized upon by the tumor to promote its own growth and progression towards metastasis. This review focuses on recent advances in understanding how an established tumor can initiate an inflammatory response via the release of pro-inflammatory mediators, such as IL-6 and IL-8, and their roles in cancer metastasis. In particular, the role of the epithelial-mesenchymal transition (EMT), a phenotypic switch observed in carcinomas that promotes progression towards metastasis, is discussed here in relation to cancer inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 1×
“In malignant tissues, TAMs constitute the most abundant cell type of the leukocyte infiltrate of the TME, where they are capable of exhibiting either anti- or pro-tumor functions [51].”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511 · cited 1×
“Initially discovered for its capacity to promote the maturation of B cells [7, 8], recent advances in understanding IL-6 signaling have revealed a central role for this cytokine in both innate and adaptive immunity [9].”
BackgroundCancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343 · cited 1×
“The biological effects of IL-8 are mediated via binding with two G protein-coupled receptors, cysteine-X-cysteine chemokine receptor-1 (CXCR1, IL-8Rα) or -2 (CXCR2, IL-8Rβ), which are normally expressed on neutrophils, monocytes and endothelial cells [30].”
BackgroundHirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S.-I., Nakajima, K., Koyama, K., Iwamatsu, A., et al. (1986) · Nature · doi:10.1038/324073a0 · Cited by 2,139 · cited 1×
“Initially discovered for its capacity to promote the maturation of B cells [7, 8], recent advances in understanding IL-6 signaling have revealed a central role for this cytokine in both innate and adaptive immunity [9].”
BackgroundByers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059
Bollrath, J., Phesse, T. J., von Burstin, V. A., Putoczki, T., Bennecke, M., Bateman, T., Nebelsiek, T., Lundgren-May, T., Canli, Ö., Schwitalla, S., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.002 · Cited by 946 · cited 1×
“In cancer, IL-6 is one of the most abundant cytokines in the TME, and its overexpression has been reported in multiple tumor types, including non-small cell lung [10], pancreatic [11], colon [12], breast [13], prostate [14] and ovarian carcinomas [15], hematological malignancies [16], and melanoma [17].”
BackgroundLütticken, C., Wegenka, U. M., Yuan, J., Buschmann, J., Schindler, C., Ziemiecki, A., Harpur, A. G., Wilks, A. F., Yasukawa, K., Taga, T., et al. (1994) · Science · doi:10.1126/science.8272872 · Cited by 814 · cited 1×
“This receptor complex then regulates the Janus kinase-signal transducer and activator of transcription 3 (STAT3) pathway, as well as other signaling pathways [21, 22].”
BackgroundTan, T. Z., Miow, Q. H., Miki, Y., Noda, T., Mori, S., Huang, R. Y., & Thiery, J. P. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404208 · Cited by 792
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007974 · Cited by 767 · cited 2×
“Blockade of CXCR2 signaling was also shown to improve the anti-tumor effect of programmed death 1 (PD1) checkpoint blockade, attributed to the alleviation of the immunosuppressive environment originated by the MDSC infiltrate [66].”
BackgroundZhang, F., Wang, H., Wang, X., Jiang, G., Liu, H., Zhang, G., Wang, H., Fang, R., Bu, X., Cai, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10561 · Cited by 580
Alfaro, C., Teijeira, A., Oñate, C., Pérez, G., Sanmamed, M. F., Andueza, M. P., Alignani, D., Labiano, S., Azpilikueta, A., Rodriguez-Paulete, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2463 · Cited by 417 · cited 1×
“For example, a recent report demonstrated the chemo-attractant ability of IL-8 to recruit granulocytic and monocytic MDSCs isolated from the peripheral blood of healthy donors and advanced cancer patients [64].”
BackgroundInhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis
Jamieson, T., Clarke, M., Steele, C. W., Samuel, M. S., Neumann, J., Jung, A., Huels, D., Olson, M. F., Das, S., Nibbs, R. J. B., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61067 · Cited by 391
Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302
Oncogene-Induced Senescence: Putting the Brakes on Tumor Development
Braig, M., & Schmitt, C. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4006 · Cited by 274
Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer
Deng, J., Wang, L., Chen, H., Hao, J., Ni, J., Chang, L., Duan, W., Graham, P., & Li, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9908 · Cited by 115
Siltuximab (CNTO 328): a promising option for human malignancies
Chen, B.-A., & Chen, R. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86438 · Cited by 65
Cited by
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
Fousek, K., Horn, L. A., & Palena, C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107692 · Cited by 359
Self-citationC-Reactive Protein and Cancer—Diagnostic and Therapeutic Insights
Hart, P. C., Rajab, I. M., Alebraheem, M., & Potempa, L. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.595835 · Cited by 275
Emerging role of tumor cell plasticity in modifying therapeutic response
Qin, S., Jiang, J., Lu, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 268
miR-223: An Effective Regulator of Immune Cell Differentiation and Inflammation
Jiao, P., Wang, X.-P., Luoreng, Z.-M., Yang, J., Jia, L., Ma, Y., & Wei, D.-W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59876 · Cited by 151
“The expression of miRNA- or DNA-based epigenetic regulators could regulate the expression of genes related to these inflammation signaling pathways, ultimately forming a gene regulatory network [67, 68].”
Background
Metadata
- Authors
- Dominguez, C., David, J. M., & Palena, C.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 47
- Pages
- 177-184
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2747503077
- Cited by
- 162
- References
- 20
- FWCI
- 7.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.